Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
Date: March 21, 2022
Issue #:
1646Summary:
Faricimab-svoa (Vabysmo– Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of neovascular
(wet) age-related macular degeneration (nAMD) and
diabetic macular edema (DME). It is the first drug to
become available i n the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available for treatment of
nAMD and DME (see Table 2).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: aflibercept Age-related macular degeneration Avastin Beovu Bevacizumab brolucizumab Byooviz Eye Eylea faricimab Lucentis Ranibizumab Susvimo Vabysmo Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Avastin | Diabetes | Drugs & Pharmacology | Endocrinology | Lucentis | Ranibizumab Injection